Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia

B O Okusanya, O T Oladapo, Q Long, P Lumbiganon, G Carroli, Z Qureshi, L Duley, J P Souza, A M Gülmezoglu, B O Okusanya, O T Oladapo, Q Long, P Lumbiganon, G Carroli, Z Qureshi, L Duley, J P Souza, A M Gülmezoglu

Abstract

Background: The pharmacokinetic basis of magnesium sulphate (MgSO4 ) dosing regimens for eclampsia prophylaxis and treatment is not clearly established.

Objectives: To review available data on clinical pharmacokinetic properties of MgSO4 when used for women with pre-eclampsia and/or eclampsia.

Search strategy: MEDLINE, EMBASE, CINAHL, POPLINE, Global Health Library and reference lists of eligible studies.

Selection criteria: All study types investigating pharmacokinetic properties of MgSO4 in women with pre-eclampsia and/or eclampsia.

Data collection and analysis: Two authors extracted data on basic pharmacokinetic parameters reflecting the different aspects of absorption, bioavailability, distribution and excretion of MgSO4 according to identified dosing regimens.

Main results: Twenty-eight studies investigating pharmacokinetic properties of 17 MgSO4 regimens met our inclusion criteria. Most women (91.5%) in the studies had pre-eclampsia. Baseline serum magnesium concentrations were consistently <1 mmol/l across studies. Intravenous loading dose between 4 and 6 g was associated with a doubling of this baseline concentration half an hour after injection. Maintenance infusion of 1 g/hour consistently produced concentrations well below 2 mmol/l, whereas maintenance infusion at 2 g/hour and the Pritchard intramuscular regimen had higher but inconsistent probability of producing concentrations between 2 and 3 mmol/l. Volume of distribution of magnesium varied (13.65-49.00 l) but the plasma clearance was fairly similar (4.28-5.00 l/hour) across populations.

Conclusion: The profiles of Zuspan and Pritchard regimens indicate that the minimum effective serum magnesium concentration for eclampsia prophylaxis is lower than the generally accepted level. Exposure-response studies to identify effective alternative dosing regimens should target concentrations achievable by these standard regimens.

Tweetable abstract: Minimum effective serum magnesium concentration for eclampsia prophylaxis is lower than the generally accepted therapeutic level.

Keywords: Eclampsia; magnesium sulphate; pharmacokinetics; pre-eclampsia; serum magnesium.

© 2015 World Health Organization; licensed by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists.

Figures

Figure 1
Figure 1
Detailed data selection process.

References

    1. The Eclampsia Trial Collaborative Group . Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995;354:1455–63.
    1. The Magpie Trial Collaborative Group . Do women with pre‐eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo controlled trial. Lancet 2002;359:1877–90.
    1. Chesley LC, Tepper I. Levels of magnesium attained in magnesium sulfate therapy for preeclampsia and eclampsia. Surg Clin North Am 1957;37:353–67.
    1. Eastman NJ, Steptoe PP. The management of pre‐eclampsia. Can Med Assoc J 1945;52:562–8.
    1. Sibai BM, Graham JM, McCubbin JH. A comparison of intravenous and intramuscular magnesium sulfate regimens in preeclampsia. Am J Obstet Gynecol 1984;150:728–33.
    1. Pritchard JA. The use of magnesium ion in the management of eclamptogenic toxaemia. Obstet Gynecol 1955;100:131–40.
    1. Charoenvidhya D, Manotaya S. Magnesium sulfate maintenance infusion in women with preeclampsia:a randomized comparison between 2 gram per hour and 1 gram per hour. J Med Assoc Thai 2013;96:395–8.
    1. Aali BS, Khazaeli P, Ghasemi F. Ionized and total magnesium concentration in patients with severe preeclampsia‐eclampsia undergoing magnesium sulfate therapy. J Obstet Gynaecol Res 2007;33:138–43.
    1. Simon J, Gray A, Duley L, Magpie Trial Collaborative Group . Cost‐effectiveness of prophylactic magnesium sulphate for 9996 women with pre‐eclampsia from 33 countries:economic evaluation of the Magpie trial. BJOG 2006;113:144–51.
    1. Conventional units to SI units—conversion factors. Available at [] Accessed 5 April 2015.
    1. Deeks J, Bossuyt P, Gatsonis C. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. 2009. [] Accessed 19 June 2015.
    1. Abbade JF, Costa RA, Martins AM, Borges VT, Rudge MV, Peraçoli JC. Zuspan's scheme versus an alternative magnesium sulfate scheme: randomized clinical trial of magnesium serum concentrations. Hypertens Pregnancy 2010;29:82–92.
    1. Apostol A, Apostol R, Ali E, Choi A, Ehsuni N, Hu B, et al. Cerebral spinal fluid and serum ionized magnesium and calcium levels in preeclamptic women during administration of magnesium sulfate. Fertil Steril 2010;94:276–82.
    1. Chen G, Li QN, Guo N. Studies on the pharmacokinetics and pharmacodynamics of MgSO4 in the treatment of pregnancy induced hypertension. Chin J Clin Pharmacol 1991;7:108–11.
    1. Chesley LC. Parenteral magnesium sulfate and the distribution, plasma levels, and excretion of magnesium. Am J Obstet Gynecol 1979;133:1–7.
    1. Chissell S, Botha JH, Moodley J, McFadyen L. Intravenous and intramuscular magnesium sulphate regimens in severe pre‐eclampsia. S Afr Med J 1994;84:607–10.
    1. Chuan FS, Charles BG, Boyle RK, Rasiah RL. Population pharmacokinetics of magnesium in preeclampsia. Am J Obstet Gynecol 2001;185:593–9.
    1. Cruikshank DP, Pitkin RM, Donnelly E, Reynolds WA. Urinary magnesium, calcium, and phosphate excretion during magnesium sulfate infusion. Obstet Gynecol 1981;58:430–4.
    1. Dayicioglu V, Sahinoglu Z, Kol E, Kucukbas M. The use of standard dose of magnesium sulphate in prophylaxis of eclamptic seizures:do body mass index alterations have any effect on success? Hypertens Pregnancy 2003;22:257–65.
    1. Ekele BA, Badung SL. Is serum magnesium estimate necessary in patients with eclampsia on magnesium sulphate? Afr J Reprod Health 2005;9:128–32.
    1. Guzin K, Goynumer G, Gokdagli F, Turkgeldi E, Gunduz G, Kayabasoglu F. The effect of magnesium sulfate treatment on blood biochemistry and bleeding time in patients with severe preeclampsia. J Matern Fetal Neonatal Med 2010;23:399–402.
    1. Handwerker SM, Altura BT, Chi DS, Altura BM. Serum ionized magnesium levels during intravenous MGSO4 therapy of preeclamptic women. Acta Obstet Gynecol Scand 1995;74:517–9.
    1. Lu J, Pfister M, Ferrari P, Chen G, Sheiner L. Pharmacokinetic‐pharmacodynamic modelling of magnesium plasma concentration and blood pressure in preeclamptic women. Clin Pharmacokinet 2002;41:1105–13.
    1. Manorot M, Tongsong T, Khettglang T. A comparison of serum magnesium sulfate levels in pregnant women with severe preeclampsia between intravenous and intramuscular magnesium sulfate regimens:a randomized controlled trial. J Med Assoc Thai 1996;79:76–81.
    1. Mason BA, Standley CA, Whitty JE, Cotton DB. Fetal ionized magnesium levels parallel maternal levels during magnesium sulfate therapy for preeclampsia. Am J Obstet Gynecol 1996;175:213–7.
    1. Phuapradit W, Saropala N, Haruvasin S, Thuvasethakul P. Serum level of magnesium attained in magnesium sulfate therapy for severe preeclampsia. Asia Oceania J Obstet Gynaecol 1993;19:387–90.
    1. Salinger DH, Mundle S, Regi A, Bracken H, Winikoff B, Vicini P, et al. Magnesium sulphate for prevention of eclampsia: are intramuscular and intravenous regimens equivalent? A population pharmacokinetic study BJOG 2013;120:894–900.
    1. Seydoux J, Girardin E, Paunier L, Béguin F. Serum and intracellular magnesium during normal pregnancy and in patients with pre‐eclampsia. Br J Obstet Gynaecol 1992;99:207–11.
    1. Shreya MS, Krishna L, Shailaja N, Bhat BS. Evaluation of single dose magnesium sulphate and Pritchard regimen in the treatment of eclampsia—a comparative study. Biomedicine (India) 2014;34:252–6.
    1. Singh A, Verma AK, Hassan G, Prakash V, Sharma P, Kulshrestha S. Serum magnesium levels in patients with preeclampsia and eclampsia with different regimens of magnesium sulphate. Global J Med Public Health 2013;2:1–5.
    1. Suvarna VNM, Ballal PK. Low dose magnesium sulphate versus Pritchard regimen for the treatment of eclampsia and imminent eclampsia. Int J Gynecol Obstet 2011;115:70–2.
    1. Taber EB, Tan L, Chao CR, Beall MH, Ross MG. Pharmacokinetics of ionized versus total magnesium in subjects with preterm labor and preeclampsia. Am J Obstet Gynecol 2002;186:1017–21.
    1. Tongsong T, Dejkijwikrom W, Tansuwannont W, Jantachai U, Siangproa U. A comparison of intravenous magnesium sulfate regimens in preeclampsia‐eclampsia between rate 1 gram and 2 grams per hour. Siriraj Hosp Gaz 1992;44:510–6.
    1. Thurnau GR, Kemp DB, Jarvis A. Cerebrospinal fluid levels of magnesium in patients with preeclampsia after treatment with intravenous magnesium sulfate: a preliminary report. Am J Obstet Gynecol 1987;157:1435–8.
    1. Wright JW, Seelig CB, Ridgway LE 3rd. Magnesium sulfate loading: preeclampsia vs preterm labor (a clinical pearl). J Am Coll Nutr 1994;13:499–501.
    1. Yoshida M, Matsuda Y, Akizawa Y, Ono E, Ohta H. Serum ionized magnesium during magnesium sulfate administration for preterm labor and preeclampsia. Eur J Obstet Gynecol Reprod Biol 2006;128:125–8.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit